Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
109 hedge funds and large institutions have $1.26B invested in Cidara Therapeutics in 2025 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 8 closing their positions.
788% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 8
513% more capital invested
Capital invested by funds: $206M → $1.26B (+$1.06B)
383% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 6
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
137% more funds holding
Funds holding: 46 → 109 (+63)
34.05% more ownership
Funds ownership: 87.3% → 121.35% (+34%)
58% less call options, than puts
Call options by funds: $38M | Put options by funds: $90.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$54.6M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$43.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34M |
| 4 |
CC
Commodore Capital
New York
|
+$28.2M |
| 5 |
BlackRock
New York
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$9.91M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.91M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$3.32M |
| 4 |
CC
Checkpoint Capital
San Francisco,
California
|
-$2.25M |
| 5 |
Millennium Management
New York
|
-$1.37M |
CDTX Hedge Fund Activity: Q2 2025 in Review
109 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2025, worth a combined $1.26B — up 513% from $206M a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new CDTX positions and 8 closed out — a net gain of 63 holders — while 29 added to existing stakes and 6 trimmed.
The largest buyer was RA Capital Management, adding an estimated $54.6M. The largest seller was VR Adviser, cutting an estimated $9.91M.
- 109 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2025, up from 46 in Q1 2025.
- Funds reported $1.26B of Cidara Therapeutics stock for Q2 2025, up 513% quarter-over-quarter.
- 71 funds opened new Cidara Therapeutics positions in Q2 2025 and 8 closed out, a net change of +63 holders.
- The largest Cidara Therapeutics buyer in Q2 2025 was RA Capital Management, an estimated $54.6M added.
- The largest Cidara Therapeutics seller in Q2 2025 was VR Adviser, an estimated $9.91M sold.
Based on aggregated 13F filings for Q2 2025.